ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.7325
0.17%
Brent Oil
84.34
-0.30%
Bitcoin
64,732.18
6.50%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acceleron Pharma Inc (XLRN)

  7. Acceleron Pharma Inc (XLRN) Noticias

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
03/01/201806:00Business WireAcceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. ShermanNASDAQ:XLRNAcceleron Pharma Inc
02/01/201806:00Business WireAcceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
18/12/201715:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
18/12/201715:50Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
10/12/201708:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annu...NASDAQ:XLRNAcceleron Pharma Inc
05/12/201706:00Business WireAcceleron to Host Conference Call & Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meetin...NASDAQ:XLRNAcceleron Pharma Inc
28/11/201712:15Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
15/11/201715:22Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
15/11/201715:01Business WireAcceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuireNASDAQ:XLRNAcceleron Pharma Inc
14/11/201715:01Business WireAcceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific ...NASDAQ:XLRNAcceleron Pharma Inc
09/11/201716:26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
07/11/201706:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
07/11/201706:00Business WireAcceleron Pharma Reports Third Quarter 2017 Operational and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
01/11/201708:19Business WireAcceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and ExpositionNASDAQ:XLRNAcceleron Pharma Inc
26/10/201706:00Business WireAcceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017NASDAQ:XLRNAcceleron Pharma Inc
05/10/201706:00Business WireAcceleron Announces Closing of Underwriters’ Option to Purchase Additional SharesNASDAQ:XLRNAcceleron Pharma Inc
25/09/201715:26Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:XLRNAcceleron Pharma Inc
21/09/201715:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:XLRNAcceleron Pharma Inc
20/09/201719:31Business WireAcceleron Announces Pricing of Public Offering of Common StockNASDAQ:XLRNAcceleron Pharma Inc
19/09/201716:09Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:XLRNAcceleron Pharma Inc
19/09/201715:12Business WireAcceleron Announces Proposed Public Offering of Common StockNASDAQ:XLRNAcceleron Pharma Inc
19/09/201715:09Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:XLRNAcceleron Pharma Inc
19/09/201710:30Business WireAcceleron Showcases Vision and Strategy at 2017 R&D DayNASDAQ:XLRNAcceleron Pharma Inc
19/09/201706:00Business WireAcceleron to Develop Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
12/09/201706:00Business WireAcceleron to Host Research and Development Day on September 19, 2017NASDAQ:XLRNAcceleron Pharma Inc
05/09/201706:00Business WireAcceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet OncologyNASDAQ:XLRNAcceleron Pharma Inc
03/08/201715:20Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XLRNAcceleron Pharma Inc
03/08/201715:05Business WireAcceleron Pharma Reports Second Quarter 2017 Operational and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
01/08/201706:00Business WireAcceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth DiseaseNASDAQ:XLRNAcceleron Pharma Inc
27/07/201706:00Business WireAcceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

NYSE
VZ
Verizon Communications
USOTC
ADDYY
Adidas (QX)
NYSE
AXP
American Express
AMEX
XLE
Energy Select Sector SPDR
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
NYSE
XOM
Exxon Mobil
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
CCOM
US500
US 500
AMEX
XLF
Financial Select Sector
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados